	Tumor Immunology: Molecularly Defined Antigens and Clinical Applications (Tumor Immunology and Immunotherapy) by Giorgio Parmiani (Editor), Michael T. Lotze (Editor) Recent advances in basic immunology and molecular biology have resulted in new immunologically based therapeutic approaches being generated and implemented in cancer clinics. The discovery of new antigens, mechanisms of antigen presentation and interplay of cells involved in antitumor immunity have made the clinical control of some cancers using biological reagents more plausible than previously thought. An invaluable source for clinicians, researchers and students, Tumor Immunology...
	Mechanisms of Tumor Escape from the Immune Response (Tumor Immunology and Immunotherapyseries, 1) by A Ochoa (Editor) Louisiana State Univ. New Orleans. Text offers a detailed discussion on the mechanisms of tumor escape from the immune response. Concepts regarding the changes in tumor cells and the immune system are addressed providing a more cohesive understanding of the process.
	Antiangiogenic Cancer Therapy by Darren W. Davis (Editor), Roy S. Herbst (Editor), James L. Abbruzzese (Editor) Top Investigators Explore the Complexities of Angiogenesis Cancer Research The targeting of tumor angiogenesis has evolved into one of the most widely pursued therapeutic strategies. However, as of yet, no antiangiogenic agent used as a monotherapy has demonstrated a survival benefit in a randomized Phase III trial. The combination of bevacizumab, the first FDA approved angiogenesis inhibitor, with cytotoxic regimens has led to survival benefits in cancer patients. This has raised important...

EDITORIAL REVIEWS

Product Description
Why a new book on angiogenesis and why now? For the first time concepts proposed over 30 years ago have found clinical validation. In the last two years the first antiangiogenic agents have been approved by the FDA for the treatment of cancer and age-related macular degeneration. Not surprisingly, this clinical success has raised a new set of basic and clinical questions that need to be addressed. Angiogenesis: From Basic Science to Clinical Applications presents the latest advances in basic science and reviews the status of the clinical applications of angiogenic growth factors and inhibitors. It explores current molecular and genetic findings on the regulation of angiogenesis, discusses the results of clinical trials and identifies the pathological conditions that are most likely to benefit from such treatments. Edited by a leading researcher in the field, the book includes contributions from multiple experts in their respective disciplines, supplemented by illustrations and photographs. A unique combination of information on basic science and clinical trials research, this book is truly a state-of-the-art review of the state of the science.

SIMILAR PRODUCTS

	Angiogenesis: An Integrative Approach from Science to Medicine by William D. Figg (Author), William D. Figg (Editor), Judah Folkman (Editor) Dr. Judah Folkman, father of angiogenesis , (1933-2008) was the Director of the Vascular Biology Program, Andrus Professor of Pediatric Surgery, and Professor of Cell Biology at Harvard University's Boston Children's Hospital. In the 1971 issue of The New England Journal of Medicine, he proposed the theory that tumor growth is angiogenesis dependent. This premise was the basis of this field of research and has become the focus of scientists worldwide. Because of Folkman's discovery and...
	Angiogenesis Assays: A Critical Appraisal of Current Techniques by Carolyn A Staton (Editor), Claire Lewis (Editor), Roy Bicknell (Editor) Angiogenesis, the development of new blood vessels from the existing vasculature, is essential for physiological growth and over 18,000 research articles have been published describing the role of angiogenesis in over 70 different diseases, including cancer, diabetic retinopathy, rheumatoid arthritis and psoriasis. One of the most important technical challenges in such studies has been finding suitable methods for assessing the effects of regulators of eh angiogenic response. While increasing...
	Antiangiogenic Cancer Therapy by Darren W. Davis (Editor), Roy S. Herbst (Editor), James L. Abbruzzese (Editor) Top Investigators Explore the Complexities of Angiogenesis Cancer Research The targeting of tumor angiogenesis has evolved into one of the most widely pursued therapeutic strategies. However, as of yet, no antiangiogenic agent used as a monotherapy has demonstrated a survival benefit in a randomized Phase III trial. The combination of bevacizumab, the first FDA approved angiogenesis inhibitor, with cytotoxic regimens has led to survival benefits in cancer patients. This has raised important...